Ronit Koren Peleg1, Gregori Fishlev2, Yair Bechor2, Jacob Bergan2, Mony Friedman2, Shlomit Koren3, Amit Tirosh3, Shai Efrati4. 1. Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Department of Internal Medicine A, Assaf Harofeh Medical Center, Zerifin 70300, Israel, Phone: +972-(0)50-5191-651, Fax: +972-(0)89778359, E-mail: ronitkoren@gmail.com. 2. The Institute of Hyperbaric Medicine, Assaf Harofeh Medical Center, Zerifin. 3. Department of Internal Medicine A, Assaf Harofeh Medical Center, Zerifin, Israel. Affiliated to Sackler School of Medicine, Tel Aviv University, Israel, Research and Development Unit, Assaf Harofeh Medical Center, Zerifin. 4. Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, The Institute of Hyperbaric Medicine, Assaf Harofeh Medical Center, Zerifin, Research and Development Unit, Assaf Harofeh Medical Center, Zerifin, Sagol School of Neuroscience, Tel-Aviv University, Tel-Aviv.
Abstract
INTRODUCTION: A decrease in blood glucose levels (BGL) during hyperbaric oxygen treatment (HBOT) is a well-recognised phenomenon, but studies of this are limited and inconclusive. This study evaluated the effect of HBOT on BGL in patients with diabetes mellitus (DM), traumatic brain injury (TBI) or stroke and healthy volunteers in a prospective, open, controlled trial. METHODS:Thirty-nine participants were enrolled and evaluated twice: once duringHBOT (90 minutes at 203 kPa), and once during a control session on normobaric air. Sessions were held up to two weeks apart and participants were instructed to eat the same diet. BGL was measured before, during and at the completion of each session. RESULTS: For the whole study group, there was a small but statistically significant decrease in BGL in both the HBOT (7.27 ± 3.66 mmol⁻¹ before to 6.71 ± 3.88 mmol ⁻¹ after, P = 0.037) and control (air) sessions (7.43 ± 3.49 mmol L⁻¹ before to 6.71 ± 3.77 mmol L⁻¹ after, P = 0.004). This fall did not differ between the two conditions (P = 0.59). Examining the three groups separately, BGL fell in all three subgroups, but this fall was only statistically significant for the air session in the diabetic group. There were no statistically significant differences in the BGL reduction when HBOT was compared to normobaric air in any of the three subgroups. CONCLUSIONS:BGL may decrease during HBOT and accordingly it should be monitored before entering the chamber. However, this decrease in BGL should probably not be attributed to the hyperbaric environment per se.
RCT Entities:
INTRODUCTION: A decrease in blood glucose levels (BGL) during hyperbaric oxygen treatment (HBOT) is a well-recognised phenomenon, but studies of this are limited and inconclusive. This study evaluated the effect of HBOT on BGL in patients with diabetes mellitus (DM), traumatic brain injury (TBI) or stroke and healthy volunteers in a prospective, open, controlled trial. METHODS: Thirty-nine participants were enrolled and evaluated twice: once during HBOT (90 minutes at 203 kPa), and once during a control session on normobaric air. Sessions were held up to two weeks apart and participants were instructed to eat the same diet. BGL was measured before, during and at the completion of each session. RESULTS: For the whole study group, there was a small but statistically significant decrease in BGL in both the HBOT (7.27 ± 3.66 mmol⁻¹ before to 6.71 ± 3.88 mmol ⁻¹ after, P = 0.037) and control (air) sessions (7.43 ± 3.49 mmol L⁻¹ before to 6.71 ± 3.77 mmol L⁻¹ after, P = 0.004). This fall did not differ between the two conditions (P = 0.59). Examining the three groups separately, BGL fell in all three subgroups, but this fall was only statistically significant for the air session in the diabetic group. There were no statistically significant differences in the BGL reduction when HBOT was compared to normobaric air in any of the three subgroups. CONCLUSIONS: BGL may decrease during HBOT and accordingly it should be monitored before entering the chamber. However, this decrease in BGL should probably not be attributed to the hyperbaric environment per se.
Authors: Joana F Sacramento; Maria J Ribeiro; Tiago Rodrigues; Elena Olea; Bernardete F Melo; Maria P Guarino; Rui Fonseca-Pinto; Cristiana R Ferreira; Joana Coelho; Ana Obeso; Raquel Seiça; Paulo Matafome; Sílvia V Conde Journal: Diabetologia Date: 2016-10-16 Impact factor: 10.122
Authors: Raelina S Howell; Theresa Criscitelli; Jon S Woods; Brian M Gillette; Harold Brem; Scott Gorenstein Journal: AORN J Date: 2018-04 Impact factor: 0.676